ChemoCentryx, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-07: Form 8-K; Period of report 2017-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-08-08: Form 8-K; Period of report 2017-08-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-08-02: Form 8-K; Period of report 2017-07-27; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2017-05-26: Form 8-K; Period of report 2017-05-25; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-07 | 8-K | 2017-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2017, ChemoCentryx, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2017. | d489664d8k.htm |
| 2017-08-08 | 8-K | 2017-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2017, ChemoCentryx, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2017. | d439107d8k.htm |
| 2017-08-02 | 8-K | 2017-07-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 27, 2017, Dr. Petrus Bekker notified ChemoCentryx, Inc. (the “Company”) of his retirement as the Company’s Chief Medical Officer, effective July 31, 2017, for family medical reasons. | d435623d8k.htm |
| 2017-05-26 | 8-K | 2017-05-25 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 ChemoCentryx, Inc. (the “Company”) held its annual meeting of stockholders on May 25, 2017. | d383268d8k.htm |
| 2017-05-10 | 8-K | 2017-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2017, ChemoCentryx, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2017. | d394374d8k.htm |
| 2017-03-14 | 8-K | 2017-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2017, ChemoCentryx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2016. | d366070d8k.htm |
| 2017-03-02 | 8-K | 2017-02-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 28, 2017, the Compensation Committee (the “Committee”) of the Board of Directors of ChemoCentryx, Inc. (the “Company”) approved a 3.5 percent increase to the base salaries to be paid to the named executive officers listed below (the “NEOs”), effective January 1, 2017. | d356439d8k.htm |
| 2017-02-14 | 8-K | 2017-02-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d314349d8k.htm |